<![CDATA[HARMONi-6: Evaluating the Safety and Generalizability of Ivonescimab in NSCLC]]>
Read the full articleYou might also wanna read
ClinicalKey
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell #LungCancer (HARMONi-6): interim ove
clinicalkey.com·1mo agoIvonescimab is Now Being Studied in Europe in HARMONi-7 Trial – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn: “Ivonescimab was one of the most talked-about drugs in lung cancer at ASCO 2026, largely on th
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
Conditions : Non-Small Cell Lung Cancer NSCLC Interventions : Biological: ABO2109 and toripalimab Sponsors : The Affiliated Nanjing Drum Tow
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting
A Multicenter Randomized Open-Label Trial Evaluating MRD-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Conditions : NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma); NSCLC;
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
Conditions : Non-Small Cell Lung Cancer; Adjuvant Therapy Interventions : Drug: Third-generation EGFR-TKI Sponsors : First Affiliated Hospit
Comments
Sign in to join the conversation.
No comments yet. Be the first.